メラノーマ治療：市場予測（2022年～2027年）

世界のメラノーマ治療の市場規模は、2020年に35億8,600万米ドルとなり、予測期間中に15.12％のCAGRで拡大し、2027年に96億800万米ドルになると予測されています。

当レポートでは、メラノーマ治療の世界市場を調査し、市場規模や予測、市場の促進要因および課題、市場動向、セグメント別の市場分析、競合情勢、主要企業のプロファイルなどの体系的な情報を提供しています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション

第2章 調査手法

• 調査データ
• 仮定

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入者の脅威
  • 競争企業間の敵対関係
• 業界のバリューチェーン分析

第5章 メラノーマ治療市場：タイプ別

• 皮膚メラノーマ
• 眼内メラノーマ
• 粘膜メラノーマ

第6章 メラノーマ治療市場：治療別

• 手術
• 免疫療法
• 標的療法
• 化学療法
• 放射線治療

第7章 メラノーマ治療市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • その他
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • その他
• アジア太平洋地域
  • 中国
  • インド
  • 韓国
  • 台湾
  • タイ
  • インドネシア
  • 日本
  • その他

第8章 競合情勢と分析

• 主要企業と戦略分析
• 新興企業と市場の有利性
• 合併、買収、合意、およびコラボレーション
• ベンダー競争力マトリックス

第9章 企業プロファイル

• Merck & Co. Inc.
• Amgen Inc.
• Iovance Biotherapeutics, Inc,
• Bristol-Myers Squibb
• F. Hoffmann-La Roche Ltd
• Eisai Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi
• AstraZeneca

The melanoma treatment market is projected to witness a CAGR of 15.12% during the forecast period to reach a market size of US$9.608 billion by 2027, increasing from US$3.586 billion in 2020.

Introduction.

In recent years, there has been a rise in the number of new cases reported due to climatic changes. These changes are increasing the incidence of melanoma patients worldwide, raising the demand for proper methods of treatment. If detected and treated early, the disease is almost always curable. The rising per capita income, better health facilities, growing health awareness, the availability of health insurance services, and advancement in medical science and bio-medicines are additionally factoring in the expansion of the market.

Geographically, North America dominates the market share. The high prevalence of skin-related cancer in the United States is a major factor contributing to the market's growth. By type, cutaneous melanoma is widely spread globally caused by too much exposure to ultraviolet rays from the sun and indoor tanning. Based on therapy, targeted therapy is gaining the market share due to lesser side effects and high efficiency rates.

Growth Factors.

• Growing regulatory approvals.

The high emphasis and consequently the elevated investment in the development of efficient treatment options are likely to have a positive impact on the growth of the market. Treatment recommendations depend on many factors, and the increasing number of regulatory approvals has made the highest impact on market growth. In 2021, Aldesleukin, Binimetinib, Braftovi (Encorafenib), Cobimetinib Fumarate, Cotellic (Cobimetinib Fumarate), Dabrafenib Mesylate, etc. were some of the approved drugs for the treatment by FDA. The emphasis of significant companies on introducing innovative treatment options and drugs will aid the market's growth in the coming years.

Impact of COVID-19 on the Melanoma Treatment Market

The pandemic has had a lagging effect on various diagnostic methods due to several restrictions and risk exposure of the comorbidity patients. A drastic reduction in skin biopsies was seen early in the COVID-19 pandemic, which disproportionately affected the elderly, females, and certain geographic regions. Efforts have been made by the government to contain the situation without further delay.

Competitive Insights.

The market leaders for the melanoma treatment market are Merck & Co. Inc., Amgen Inc., Iovance Biotherapeutics, Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd., Novartis AG, Pfizer Inc., Sanofi, and AstraZeneca.

• In 2021, Oncosec Medical Inc. and Merck and Co. collaborated to study phase III metastatic melanoma.
• In 2021, Amgen completed the acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share and is set to acquire Teneobio, a privately held, clinical-stage biotechnology company.
• In 2020, Iovance Biotherapeutics, Inc sold $500 million of its common stock, subject to market and other conditions, in an underwritten public offering. In 2021, there has been certain turmoil, and the company is looking for buy-out options.
• In 2019, Bristol-Myers Squibb Company and Celgene Corporation entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene for approximately $74 billion to create an innovative biopharma company.
• In 2020, Novartis AG acquired The Medicines Company, and in 2018 GlaxoSmithKline plc reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion.
• In 2020, FDA approved AstraZeneca and Merck & Co.'s drug selumetinib to treat neurofibromatosis type 1, or NF1, a rare and typically inherited disease that causes tumors to grow inside nerve sheaths. Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.

Segmentation:

• By Type

Cutaneous Melanoma

Ocular Melanoma

Mucosal Melanoma

• By Therapy

Surgery

Immunotherapy

Targeted Therapy

Chemotherapy

Radiation Therapy

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• UK
• Germany
• France
• Spain
• Others

Middle East and Africa

• Saudi Arabia
• Israel
• Others

Asia Pacific

• Japan
• China
• India
• Indonesia
• Taiwan
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Definition
• 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porters Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Powers of Buyers
  • 4.3.3. Threat of Substitutes
  • 4.3.4. The Threat of New Entrants
  • 4.3.5. Competitive Rivalry in Industry
• 4.4. Industry Value Chain Analysis

5. MELANOMA TREATMENT MARKET BY TYPE

• 5.1. Cutaneous Melanoma
• 5.2. Ocular Melanoma
• 5.3. Mucosal Melanoma

6. MELANOMA TREATMENT MARKET BY THERAPY

• 6.1. Surgery
• 6.2. Immunotherapy
• 6.3. Targeted Therapy
• 6.4. Chemotherapy
• 6.5. Radiation Therapy

7. MELANOMA TREATMENT MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. United States
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. United Kingdom 
  • 7.4.4. Spain 
  • 7.4.5. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Israel
  • 7.5.4. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. India
  • 7.6.3. South Korea
  • 7.6.4. Taiwan
  • 7.6.5. Thailand
  • 7.6.6. Indonesia 
  • 7.6.7. Japan
  • 7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Emerging Players and Market Lucrative
• 8.3. Mergers, Acquisition, Agreements, and Collaborations
• 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

• 9.1. Merck & Co. Inc.
• 9.2. Amgen Inc.
• 9.3. Iovance Biotherapeutics, Inc,
• 9.4. Bristol-Myers Squibb 
• 9.5. F. Hoffmann-La Roche Ltd
• 9.6. Eisai Co., Ltd.
• 9.7. Novartis AG
• 9.8. Pfizer Inc.
• 9.9. Sanofi
• 9.10. AstraZeneca